Tennessee inmate's heart device must be turned off before execution to avoid shock risk, judge rules
The order by Nashville Chancellor Russell Perkins comes ahead of the Aug. 5 execution of Byron Black. Black's attorneys have said that the implantable cardioverter-defibrillator could shock him in an attempt to restore his heart's normal rhythm after the single dose of pentobarbital, with the potential for multiple rounds of shocks and extreme pain and suffering.
The order requires the state to deactivate the device moments before administering the lethal injection, including having medical or certified technician professionals, plus equipment, on hand. The lower-court judge said the order will not serve to delay the execution, something he said he does not have the authority to do. He also said it doesn't add an undue administrative or logistical burden for the state.
Black's attorneys say the only surefire way to shut off the device is for a doctor to place a programming device over the implant site, sending it a deactivation command. It is unclear how quickly the state could find a medical professional willing to do the deactivation. Additionally, the state is almost certain to file a quick appeal.
This latest ruling comes after extensive back-and-forth between Tennessee officials and Black's legal team, who have argued in a number of court filings that their client's cognitive disabilities mean he isn't competent for execution. One of them was a request sent to Tennessee Gov. Bill Lee for Black's clemency, asking the governor to commute his sentence to life in prison.
"Mr. Black, who lives with an intellectual disability, has been on death row for 25 years," the letter read. "From infancy, he suffered from the effects of prenatal alcohol exposure, resulting in Fetal Alcohol Syndrome. As a toddler, he was exposed to toxic lead, compounding his lifelong cognitive and developmental impairments."
Now 69 and wheelchair-bound, Black suffers from dementia, multiple organ failures, including heart failure, diabetes and prostate cancer, according to his attorneys, who also noted in their clemency request that the inmate has an implanted device to regulate his heart.
The implantable cardioverter-defibrillator is a small, battery-powered electronic instrument that is surgically implanted in someone's chest, usually near the left collarbone. Black's was inserted in May 2024. It serves as a pacemaker and an emergency defibrillator. At a two-day hearing this week, experts offered clashing testimony on how it would act during the execution and what Black could feel if he is shocked.
Attorneys for the state deemed it highly unlikely that the pentobarbital would trigger the device's defibrillating function, and if it did, they say he would be unconscious and unaware, and unable to perceive pain. The state also said the lower-court judge lacked authority to order the device disabled.
Black's attorneys say the state is relying on studies that confuse unawareness with unresponsiveness. The inmate's team says research shows pentobarbital renders people unresponsive and causes them to experience amnesia after they undergo an operation, but it doesn't make them unaware or unable to feel pain..
Kelley Henry, an attorney for Black, said she is relieved by the ruling.
"It's horrifying to think about this frail old man being shocked over and over as the device attempts to restore his heart's rhythm even as the State works to kill him," Henry said in a statement. "Today's ruling averts that torturous outcome."
A Tennessee attorney general's office spokesperson did not immediately respond to requests for comment Friday evening. Its previous filings say Black is trying to further delay justice for brutal murders.
Black was convicted in the 1988 shooting deaths of girlfriend Angela Clay, 29, and her two daughters, Latoya, 9, and Lakeisha, 6. Prosecutors said Black was in a jealous rage when he shot the three at their home. At the time, Black was on work-release while serving time for shooting and wounding Clay's estranged husband.
Black has already seen three execution dates come and go, thanks to the COVID-19 pandemic and a pause on executions from Gov. Bill Lee after the Department of Correction was found to not be testing the execution drugs for potency and purity as required. Black's execution would be the second one under a pentobarbital protocol released in December.
If Black's attorneys could prove their client's intellectual disability, executing him would violate Tennessee's Constitution. But the state Supreme Court recently declined to order a hearing over whether he is incompetent to be executed. A U.S. Supreme Court effort remains pending.
The clemency request also said Black would have been spared the execution under a 2021 state law if he had delayed filing his intellectual disability claim.
"If this execution is allowed to move forward, Mr. Black will be the first intellectually disabled person executed by Tennessee in the modern era of the death penalty," his attorneys wrote in that filing.
Black's motion related to his heart device came within a general challenge he and other death row inmates filed against the state's new execution protocol. The trial isn't until 2026.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
SIGA to Host Business Update Call on August 5, 2025 Following Release of Second-Quarter 2025 Results
NEW YORK, July 29, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Tuesday, August 5, 2025. Participating in the call will be Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer. A live webcast of the call will also be available on the Company's website at in the Investor Relations section of the site, or by clicking here. Please log in approximately 5-10 minutes prior to the scheduled start time. Participants may access the call by dialing 1-800-717-1738 for domestic callers or 1-646-307-1865 for international callers. A replay of the call will be available for two weeks by dialing 1-844-512-2921 for domestic callers or 1-412-317-6671 for international callers and using Conference ID: 1130215. The archived webcast will be available in the Investor Relations section of the Company's website. About SIGA SIGA is a commercial-stage pharmaceutical company and leader in global health focused on the development of innovative medicines to treat and prevent infectious diseases. With a primary focus on orthopoxviruses, we are dedicated to protecting humanity against the world's most severe infectious diseases, including those that occur naturally, accidentally, or intentionally. Through partnerships with governments and public health agencies, we work to build a healthier and safer world by providing essential countermeasures against these global health threats. Our flagship product, TPOXX® (tecovirimat), is an antiviral medicine approved in the U.S. and Canada for the treatment of smallpox and authorized in Europe, the UK, and Japan for the treatment of smallpox, mpox (monkeypox), cowpox, and vaccinia complications. For more information about SIGA, visit Contacts:Suzanne Harnettsharnett@ and Investors Media Jennifer Drew-Bear, Edison GroupJdrew-bear@ Holly Stevens, CG Lifehstevens@
Yahoo
5 hours ago
- Yahoo
Sarepta shares rebound after shipments of gene therapy Elevidys resume in US
(Reuters) -Sarepta Therapeutics shares surged more than 30% before the bell on Tuesday, as analysts said the resumption of U.S. shipments for its muscular gene therapy partially removes financial headwinds and decreases the risk of market withdrawal. The company said on Monday it would resume shipments of Elevidys — approved in the U.S. to treat a rare condition called Duchenne muscular dystrophy — to patients who can walk. U.S. shipments to patients who cannot walk independently are still halted, following the death of two teenage boys earlier this year. These incidents brought heightened regulatory scrutiny to Sarepta in recent weeks, while the pause of shipments raised concerns about the future of Elevidys — the company's largest revenue generator. Sarepta's announcement followed the U.S. Food and Drug Administration's recommendation that the voluntary hold on shipments be removed after a probe showed the death of an 8-year-old boy in Brazil was not related to Elevidys. Wall Street analysts said the resumption of shipments would allow Sarepta to fulfill its near-term payments to partner Arrowhead and maintain access to its debt facilities. "The FDA's recommendation and the resumption of commercial treatment in the U.S. virtually eliminate the risk of Elevidys being formally withdrawn from the market," said William Blair analyst Sami Corwin. While the decision allows some patients to regain access to the treatment, analysts warned that patients and doctors could show hesitancy in light of the recent hit to reputation. "It remains to be seen how the news headlines regarding the patient deaths will affect commercial interest in the near term," Corwin said. Sarepta's partner Roche had also stopped Elevidys shipments in certain countries outside the U.S. Shares of Sarepta surged 36% to $18.85 in premarket trading. They have fallen more than 80% since the first Elevidys-related death was reported in March. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Forbes
5 hours ago
- Forbes
Sweeping Problems Under The Rug By The Feds Doesn't Make Them Go Away
A man walks his dog past a homeless man sleeping under a message painted on a boarded up shop in San ... More Francisco, California on April, 1, 2020, during the novel coronavirus outbreak. - The US death toll from the coronavirus pandemic topped 5,000 late on April 1, according to a running tally from Johns Hopkins University. (Photo by Josh Edelson / AFP) (Photo by JOSH EDELSON/AFP via Getty Images) For decades, every administration, every Congress, put many things off for someone else to deal with. No one can get everything done all the time, that's understandable. But many current economic and social programs aren't a result of juggling what might be possible. Instead, they have become the ultimate attempt to kick every can down the road. That doesn't solve problems. It only hides them and allows them to grow and fester. One of the current examples is homelessness. Here is a statement out of the presidential executive order, Ending Crime And Disorder On America's Streets: 'The overwhelming majority of these individuals are addicted to drugs, have a mental health condition, or both. Nearly two-thirds of homeless individuals report having regularly used hard drugs like methamphetamines, cocaine, or opioids in their lifetimes. An equally large share of homeless individuals reported suffering from mental health conditions.' Homelessness is a problem in many parts of the country. And, yes, people on the streets are often troubled in one way or another. However, the entire executive order is a rhetorical setup, claiming that 'nearly two-thirds' of the individuals reporting having used 'hard drugs like methamphetamines, cocaine, or opioids in their lifetimes.' No source for the statistic that is then delivered to deemphasize that any such use might have been long before. And then a statement that an 'equally large share of homeless individuals reported suffering from mental health conditions.' No source, again, and no explanation of what mental health conditions mean. Broadly defined enough, like any amount of depression, anxiety, discomfort, and so on, it could include everyone in the country. Next, a combination of claiming that spending by the federal government and states has run tens of billions on failed programs 'that address homelessness but not its root causes.' After claiming that homeless people leave 'other citizens vulnerable to public safety threats' comes the statement, 'Shifting homeless individuals into long-term institutional settings for humane treatment through the appropriate use of civil commitment will restore public order.' After stating that previous spending never looked at root causes, presuming that the administration knows the root causes, the proffered solution is to lock people away. The message is to ignore the problem and put it out of sight. The point isn't really for safety, because most dangerous behavior in the country doesn't come from homeless people. It's for comfort and to pretend everything is fine. This has economic and social implications. Institutionalize where? Privately owned prisons where someone makes a lot of money from incarcerations? Hospitals that have been financially struggling but will even more now that Medicaid has been so thoroughly cut? Similar issues come in arguments over diversity, equity, and inclusion, or DEI. The administration wants it purged not only from websites and government discussions, but from corporations, universities, and anywhere else the term might appear. Again, the communication expressed by action is to strike any mention of the topic anywhere, to bury it from consciousness as though that makes issues go away. It never does. Other parts of life are no different. Corporations want to promote the use of the most recent forms of artificial intelligence. Traditionally, the argument executives would use is not that technology was about enabling job cuts, but to free people up to do more useful and interesting work. That mask has finally begun to slip as CEOs and their corporations boast of shrinking their workforces. Ultimately, this will lead to fewer people being employed, greater degrees of consumer financial struggle, and economic weakness. But, again, that all gets brushed under the carpet. No society can long stand with such undermining. So long as problems are ignored, they likely grow worse until there comes a point that they demand more resources than are available.
